ATE209887T1 - Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel - Google Patents

Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel

Info

Publication number
ATE209887T1
ATE209887T1 AT94913349T AT94913349T ATE209887T1 AT E209887 T1 ATE209887 T1 AT E209887T1 AT 94913349 T AT94913349 T AT 94913349T AT 94913349 T AT94913349 T AT 94913349T AT E209887 T1 ATE209887 T1 AT E209887T1
Authority
AT
Austria
Prior art keywords
hair
liposomes
encapsulating
delivery
beneficial
Prior art date
Application number
AT94913349T
Other languages
English (en)
Inventor
Lingna Li
Valeryi K Lishko
Original Assignee
Anticancer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26718278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE209887(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/181,471 external-priority patent/US5641508A/en
Application filed by Anticancer Inc filed Critical Anticancer Inc
Application granted granted Critical
Publication of ATE209887T1 publication Critical patent/ATE209887T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
    • C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
    • C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/10—Preparations for permanently dyeing the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18001—Tyrosinase (1.14.18.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94913349T 1993-04-02 1994-04-01 Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel ATE209887T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4155393A 1993-04-02 1993-04-02
US08/181,471 US5641508A (en) 1994-01-13 1994-01-13 Method for delivering melanin to hair follicles
PCT/US1994/003634 WO1994022468A1 (en) 1993-04-02 1994-04-01 Method for delivering beneficial compositions to hair follicles

Publications (1)

Publication Number Publication Date
ATE209887T1 true ATE209887T1 (de) 2001-12-15

Family

ID=26718278

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94913349T ATE209887T1 (de) 1993-04-02 1994-04-01 Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel

Country Status (8)

Country Link
US (5) US5753263A (de)
EP (1) EP0692972B2 (de)
JP (1) JP2950520B2 (de)
AT (1) ATE209887T1 (de)
AU (1) AU6554594A (de)
CA (1) CA2159626C (de)
DE (1) DE69429337T3 (de)
WO (1) WO1994022468A1 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022468A1 (en) 1993-04-02 1994-10-13 Anticancer, Inc. Method for delivering beneficial compositions to hair follicles
US7556825B2 (en) * 1993-04-02 2009-07-07 Anticancer, Inc. Method for promoting hair growth
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US5480901A (en) * 1994-10-07 1996-01-02 Zynaxis, Inc. Method for reducing unwanted cellular adhesions
US6844326B2 (en) * 1995-06-07 2005-01-18 Anticancer, Inc. Treatment of alopecia
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US6261597B1 (en) * 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
US6459805B1 (en) * 1996-03-26 2002-10-01 Childrens Hospital Los Angeles Fluorescence digital imaging microscopy system
US5766214A (en) * 1996-04-18 1998-06-16 Mehl, Sr.; Thomas L. Melanin enhanced photothermolysis hair removal
CA2256456A1 (en) * 1996-05-30 1997-12-11 The University Of British Columbia Enhanced efficacy of liposomal antisense delivery
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
ES2356342T3 (es) * 1998-01-05 2011-04-07 The University Of Washington Mejora de transporte utilizando agentes de alteración de membrana.
US6348348B1 (en) * 1998-04-07 2002-02-19 The Carnegie Institution Of Washington Human hairless gene and protein
AU753270B2 (en) 1998-05-21 2002-10-10 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6372489B1 (en) 1998-10-27 2002-04-16 Anticancer, Inc. Method and model for hair pigmentation
WO2000024895A2 (en) * 1998-10-27 2000-05-04 Anticancer, Inc. Method and model for hair pigmentation
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
CA2380640A1 (en) * 1999-08-18 2001-02-22 Kyowa Hakko Kogyo Co., Ltd. Hair-growing agent
TWI278622B (en) * 1999-10-29 2007-04-11 Shiseido Co Ltd Quantitative hair folliculi absorption method and skin absorption measurement method
EP1237582B1 (de) * 1999-12-10 2011-09-14 AntiCancer, Inc. Verfahren zur einführung von genen in säugetiere
US7737108B1 (en) 2000-01-07 2010-06-15 University Of Washington Enhanced transport using membrane disruptive agents
US20030017183A1 (en) * 2000-01-11 2003-01-23 Pollock David E. Dermatological suspensions(micro-matrix)
WO2001085142A1 (en) 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
EP1349564A2 (de) * 2000-06-22 2003-10-08 HOLICK, Michael F Lokale applikation von peptiden zur regulation der zellproliferation und zelldifferenzierung
US20040022838A1 (en) * 2001-06-20 2004-02-05 Holick Michael F. Regulation of cell proliferation and differentiation using topically applied peptides
WO2002007674A2 (en) * 2000-07-21 2002-01-31 Ceramoptec Industries, Inc. Enhancing compound penetration into hair follicles
US20040013719A1 (en) * 2000-10-06 2004-01-22 Holick Michael F. Regulation of cell proliferation and differentiation using topically applied nucleric acid molecules
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
WO2002087530A1 (en) * 2001-04-27 2002-11-07 The General Hospital Corporation Tyrosinase assay
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
US7858117B2 (en) * 2002-02-21 2010-12-28 Novosom Ag Amphoteric liposomes and their use
WO2003083443A2 (en) * 2002-03-29 2003-10-09 University Of Florida Lipid mediated screening of drug candidates for identification of active compounds
EP1352631A1 (de) * 2002-04-08 2003-10-15 Kao Corporation Haarfärbemittel
FR2840531B1 (fr) * 2002-06-11 2004-10-29 Oreal Composition cosmetique comprenant un agent mimetique de l'activite de la dopachrome tautomerase (trp-2) pour lutter contre la canitie
US7585514B2 (en) * 2002-06-11 2009-09-08 L'oreal Administration of agents mimicking DOPAchrome tautomerase (TRP-2) activity for protecting hair follicle melanocytes
EP1515688B1 (de) * 2002-06-11 2013-07-24 L'Oréal Verwendung vom Salen-Mangan-Komplexen als Schutzmittel für Melanocyten in Haarfollikeln und kosmetische Verwendungen
FR2840530B1 (fr) * 2002-06-11 2004-12-24 Oreal Composition cosmetique comprenant un agent inducteur de l'expression de la dopachrome tautomerase (trp-2) pour lutter contre la canitie
JP2006504932A (ja) * 2002-09-20 2006-02-09 ザ ジェネラル ホスピタル コーポレーション 皮膚損傷を予防するための方法および組成物
CA2509914A1 (en) * 2002-12-11 2004-06-24 Ferrosan A/S Gelatine-based materials as swabs
CA2515440A1 (fr) * 2003-02-12 2004-09-02 L'oreal Utilisation d'un inhibiteur de 15-hydroxy prostaglandine deshydrogenase pour favoriser la pigmentation de la peau ou des phaneres
FR2850864B1 (fr) * 2003-02-12 2007-04-13 Oreal Utilisation d'un inhibiteur de 15-hydroxy prostaglandine deshydrogenase pour favoriser la pigmentation de la peau ou des phaneres
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
EP1628666B1 (de) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Verbindungen und ihre verwendungen zur modulierung von amyloid beta
DE10340373A1 (de) * 2003-08-30 2005-03-24 Henkel Kgaa Verfahren zur Bestimmung von Haarzyklus-Marken
US20050058614A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
EP2329831A3 (de) 2003-11-05 2011-08-17 Osteoscreen, Inc. Stimulierung des Haarwachstums durch Ginko Biloba-Flavanoide
US8535711B2 (en) * 2004-01-23 2013-09-17 Teikoku Pharma Usa, Inc. Medication disposal system
US7867511B2 (en) * 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
US7923031B2 (en) * 2004-01-30 2011-04-12 Ferrosan Medical Devices A/S Haemostatic sprays and compositions
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US8168600B2 (en) * 2004-04-23 2012-05-01 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
WO2005105157A2 (en) * 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Ofnew York INHIBITION OF HAIRLESS PROTEIN mRNA
US7706873B2 (en) 2004-05-05 2010-04-27 Mario Ammirati System and method for controlled delivery of a therapeutic agent to a target location within an internal body tissue
DE102004028465A1 (de) * 2004-06-11 2005-12-29 Henkel Kgaa Färbemittel für keratinhaltige Fasern
RU2369408C2 (ru) * 2004-07-09 2009-10-10 Ферросан А/С Гемостатическая композиция, включающая гиалуроновую кислоту
US20060073117A1 (en) * 2004-10-01 2006-04-06 Stowers Institute For Medical Research Methods and compositions for controlling hair follicle stem cell fate
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US7524510B2 (en) * 2005-02-23 2009-04-28 The Uab Research Foundation Alkyl-glycoside enhanced vaccination
US20080193386A1 (en) * 2005-03-24 2008-08-14 Medigenes Co., Ltd Compositions for Treating Alopecia or Promoting Hair Growth
WO2006128084A2 (en) * 2005-05-27 2006-11-30 The Trustees Of Columbia University In The City Of New York Trps1-mediated modulation of hair growth
EP1764091B1 (de) * 2005-09-15 2017-08-30 Marina Biotech, Inc. Verbesserungen für, oder in Bezug auf amphotere Liposomen
US7718193B2 (en) * 2006-03-16 2010-05-18 University Of Washington Temperature- and pH-responsive polymer compositions
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
DE102006060154A1 (de) * 2006-12-18 2008-06-19 Henkel Kgaa Verfahren zur molekularen Charakterisierung von ergrautem und pigmentiertem Haar
US7981688B2 (en) 2007-03-08 2011-07-19 University Of Washington Stimuli-responsive magnetic nanoparticles and related methods
DK3091075T3 (en) 2007-04-09 2018-07-16 Univ Arkansas FUSION PROTEINS OF COLLAGEN-BINDING DOMAIN AND PARATHYRO OIDA HORMON
FR2918885B1 (fr) 2007-07-17 2009-08-28 Oreal Utilisation d'extrait de bacterie cultivee sur eau thermale pour diminuer les poches et/ou les cernes perioculaires
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
AU2008329327B2 (en) 2007-11-26 2015-07-16 Roche Innovation Center Copenhagen A/S LNA antagonists targeting the androgen receptor
US8642831B2 (en) * 2008-02-29 2014-02-04 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
FR2928546B1 (fr) * 2008-03-17 2013-08-02 Oreal Utilisation d'inhibiteurs de la dopa decarboxylase pour la pigmentation capillaire.
FR2928544A1 (fr) * 2008-03-17 2009-09-18 Oreal Utilisation d'inhibiteurs de la dopamine-beta hydroxylase pour la pigmentation capillaire.
FR2928543B1 (fr) * 2008-03-17 2013-08-02 Oreal Utilisation d'inhibiteurs de la xanthine oxydase pour la pigmentation capillaire
FR2928545B1 (fr) * 2008-03-17 2013-08-02 Oreal Utilisation d'inhibiteurs de monoamines oxydases pour la pigmentation capillaire
FR2929118B1 (fr) 2008-03-28 2010-05-07 Oreal Utilisation de l'association de madecassoside et/ou de terminoloside et d'une arginine pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
FR2929117B1 (fr) 2008-03-28 2010-05-07 Oreal Utilisation de l'association du 2,4-diaminopyrimidine 3-n-oxyde et du madecassosside et/ou du terminoloside pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
US8426214B2 (en) * 2009-06-12 2013-04-23 University Of Washington System and method for magnetically concentrating and detecting biomarkers
US20110117668A1 (en) * 2009-11-09 2011-05-19 University Of Washington Through Its Center For Commercialization Self-powered smart diagnostic devices
US9080933B2 (en) 2009-11-09 2015-07-14 University Of Washington Through Its Center For Commercialization Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates
AU2011326034B2 (en) 2010-11-12 2016-02-04 Roche Innovation Center Copenhagen A/S Compositions and methods for treating androgen receptor dependent disorders including cancers
US9579283B2 (en) 2011-04-28 2017-02-28 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
CN103917224A (zh) * 2011-07-19 2014-07-09 Stc·Unm公司 基于在癌症的炎症环境释放治疗性负载的腹膜内给药的纳米载体
BR112014005543A2 (pt) 2011-09-30 2017-03-21 Teikoku Pharma Usa Inc sistema de descarte de medicação geral
JP5964435B2 (ja) 2011-09-30 2016-08-03 テイコク ファーマ ユーエスエー インコーポレーテッド 経皮パッチ廃棄システム
CA2859412C (en) 2011-12-14 2021-05-25 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments
EP2805713B1 (de) 2012-01-18 2018-10-10 Bioneer Corporation Samirna-komplex mit magnetischen nanopartikeln und verfahren zur herstellung davon
US9526765B2 (en) 2012-02-09 2016-12-27 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
JP6241624B2 (ja) 2012-03-06 2017-12-06 フェロサン メディカル デバイシーズ エイ／エス 止血ペーストを収容する加圧容器
CN104349797B (zh) 2012-06-12 2017-10-27 弗罗桑医疗设备公司 干止血组合物
WO2014009857A2 (en) * 2012-07-10 2014-01-16 Koninklijke Philips N.V. Release of molecules from container by selective heating of hair
WO2014016118A1 (en) * 2012-07-26 2014-01-30 Unilever N.V. A method of preparing recombinant human tyrosinase
US10011874B2 (en) 2013-02-25 2018-07-03 Novartis Ag Androgen receptor mutation
CA2912357C (en) 2013-06-21 2019-12-31 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
CA2917299C (en) 2013-07-05 2020-07-21 Bioneer Corporation Improved nanoparticle type oligonucleotide structure having high efficiency and method for preparing same
CN105705639A (zh) 2013-07-05 2016-06-22 柏业公司 登革病毒相关的基因特异性siRNA、包含该siRNA的双链寡RNA分子、和包含它们的用于抑制登革病毒复制的组合物
KR20150006742A (ko) * 2013-07-09 2015-01-19 (주)바이오니아 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
JP6489485B2 (ja) 2013-12-11 2019-03-27 フェロサン メディカル デバイシーズ エイ／エス 押し出し増強因子を含んでいる乾燥組成物
CN106459974A (zh) 2014-04-04 2017-02-22 柏业公司 新颖的双链寡rna和包含它的用于预防或治疗纤维化或呼吸系统疾病的药物组合物
JP6726852B2 (ja) 2014-10-13 2020-07-22 フェッローサン メディカル ディバイス エー／エス 止血および創傷治癒に使用するための乾燥組成物
JP6747650B2 (ja) 2014-12-24 2020-08-26 フェロサン メディカル デバイシーズ エイ／エス 第１の物質と第２の物質を保持し混合するためのシリンジ
EP3316930B1 (de) 2015-07-03 2019-07-31 Ferrosan Medical Devices A/S Spritze zum mischen zweier komponenten und zum aufrechterhalten eines vakuums im lagerzustand
JP7397440B2 (ja) 2017-02-10 2023-12-13 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー コラーゲン結合薬剤組成物およびその使用方法
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
ES2968412T3 (es) 2018-05-09 2024-05-09 Ferrosan Medical Devices As Método para preparar una composición hemostática
CN112245571A (zh) * 2020-09-16 2021-01-22 陕西中鸿科瑞再生医学研究院有限公司 一种用于乌发的脂质体制剂及其制备方法
US12005134B2 (en) * 2021-06-30 2024-06-11 Abe Pharmaceutical Composition for stimulating facial hair growth and methods of manufacturing a composition for stimulating facial hair growth

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5147778B2 (de) 1973-12-01 1976-12-16
US4925661A (en) * 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US4957735A (en) * 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US4755388A (en) * 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
GB8604360D0 (en) * 1986-02-21 1986-03-26 Univ Dundee Stimulation of hair growth
US4806344A (en) 1987-01-05 1989-02-21 Gaskin Frances C Sun protectant composition and method
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US5290562A (en) * 1987-11-27 1994-03-01 L V M H Recherche Compositions and methods employing liposomes including tyrosine or a tyrosine derivative
FR2628317B1 (fr) * 1988-03-09 1991-11-08 Lvmh Rech Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un extrait de scutellaria, ou au moins un flavonoide tel que baicaleine ou baicaline et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite anti-allergique, anti-inflammatoire ou anti-vieillissement, l'incorporant
US5190762A (en) * 1988-07-06 1993-03-02 Applied Genetics, Inc. Method of administering proteins to living skin cells
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
IT1231260B (it) * 1988-11-16 1991-11-28 Sergio Bertini Curri Farmaco e metodo per aumentare volume e velocita' del flusso microcircolatorio capillare a livello cutaneo
US5618798A (en) * 1989-04-20 1997-04-08 Bar-Shalom; Daniel Use of sucralfate to treat baldness
FR2648132B1 (fr) * 1989-06-08 1991-09-13 Thorel Jean Composes pigmentogenes, leurs vehicules de diffusion, compositions les contenant et leur procede de preparation
FR2654935B1 (fr) * 1989-11-28 1994-07-01 Lvmh Rech Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
GB9014221D0 (en) * 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
FR2669225B1 (fr) * 1990-11-21 1993-11-12 Lvmh Recherche Gie Utilisation de saponines de medicago pour la preparation de compositions cosmetiques ou pharmaceutiques, notamment dermatologiques.
US5723149A (en) 1990-11-21 1998-03-03 Lvmh Recherche Use of medicago saponins for the preparation of cosmetic or pharmaceutical compositions, especially dermatological compositions, promoting renewal of the epidermis, stimulating hair regrowth or delaying hair loss
DE4113346A1 (de) * 1991-04-24 1992-10-29 Lang Erich Zubereitung zur kraeftigung und regeneration des haarwuchses
WO1994022468A1 (en) 1993-04-02 1994-10-13 Anticancer, Inc. Method for delivering beneficial compositions to hair follicles
AU4228093A (en) * 1992-05-04 1993-11-29 David L. Berliner Process for absorbing ultraviolet radiation using dispersed melanin
US5641509A (en) * 1992-06-26 1997-06-24 Lancaster Group Ag Preparation for topical use
FR2694768B1 (fr) * 1992-07-30 1994-12-23 Pasteur Institut Séquences d'oligonucléotides pour la détection spécifique de mollicutes par amplication de gènes conservés.
US5302389A (en) * 1992-08-17 1994-04-12 Board Of Regents, The University Of Texas System Method for treating UV-induced suppression of contact hypersensitivity by administration of T4 endonuclease

Also Published As

Publication number Publication date
EP0692972A1 (de) 1996-01-24
EP0692972A4 (de) 1998-05-06
DE69429337D1 (de) 2002-01-17
US6261596B1 (en) 2001-07-17
US5965157A (en) 1999-10-12
WO1994022468A1 (en) 1994-10-13
EP0692972B1 (de) 2001-12-05
JP2950520B2 (ja) 1999-09-20
DE69429337T3 (de) 2012-08-30
US6224901B1 (en) 2001-05-01
US5753263A (en) 1998-05-19
JPH08511510A (ja) 1996-12-03
AU6554594A (en) 1994-10-24
EP0692972B2 (de) 2012-03-21
CA2159626A1 (en) 1994-10-13
CA2159626C (en) 2001-10-02
DE69429337T2 (de) 2002-10-10
US5914126A (en) 1999-06-22

Similar Documents

Publication Publication Date Title
ATE209887T1 (de) Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
DE69837274D1 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
EP0796081B1 (de) Elektrophoretischer apparat und verfahren zur anwendung von therapeutischen-, kosmetischen- und farblösungen im haar
US5470577A (en) Stimulation of tanning by DNA fragments or single-stranded DNA
US8946402B2 (en) Inhibition of hairless protein mRNA
US4935231A (en) Use of thioredoxin, thioredoxin-derived, or thioredoxin-like dithiol peptides in hair care preparations
DE59611371D1 (de) Verfahren zur Herstellung von Erythropoietin frei von tierischen Proteinen
US20060270621A1 (en) Inhibition of hair growth with RNAi targeting desmoglein 4 and nude mRNAs
NO921875L (no) Metallpeptidpreparater og fremgangsmaater for aa stimulere haarvekst
BR0108959A (pt) Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
ATE239498T1 (de) Entzündungshemmende zusammensetzung
DE3580531D1 (de) Verfahren zur herstellung lagerstabiler waessriger praeparate von anionischen farbstoffen.
MXPA00006306A (es) Compuestos del canal de ion del cerebro o corazon, regulados por nucleotidos ciclicos y usos de los mismos.
DE69331144D1 (de) Entwicklung eines vektors zur erreichung von genexpression in der epidermis transgener tiere
JPH10279501A (ja) 育毛剤
IT1228210B (it) Procedimento per la introduzione di dna esogeno nelle cellule somatiche e germinali di animali.
ATE336992T1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz- erkrankungen
WO2000008157A3 (en) Human anion transporter genes atnov
DE59510829D1 (de) Gentherapeutisches verfahren unter verwendung von dna-vektoren ohne selektionsmarker-gen
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
BR9002240A (pt) Processo para a preparacao de uma composicao conservada apropriada para aplicacao topica a pele e composicao
DE19514647B4 (de) Verwendung von Chromogranin A zum Fördern des Haarwuchses
WO1995035373A3 (en) Nucleic acid molecules encoding human contactin
Hoperskaya et al. Isolation of a Factor Mediating Melanogenic Induction in Pigment Cells of Xenopus Laevis: (pigment cells/ap/ap mutant/melanocyte differentiation/embryonic induction)
ATE298000T1 (de) Eine methode zur erhöhung der transfektion von zellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties